Budapest and Pécs, Hungary - July 23-30, 2025 - The VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty^®), independently developed by MicroPort CardioFlow Medtech Corporation (02160.HK), has successfully completed its first 12 commercial clinical applications in Hungary.

The inaugural procedures were performed by Prof. Béla Merkely and Dr. Levente Molnar from Semmelweis University Hospital, Prof. Péter Andréka and Dr. Géza Fontos from Gottsegen National Cardiovascular Center, as well as Dr. Kertész, Dr. Kracskó and Dr. Szokol from Debrecen University (Pécs) under the guidance of renowned expert Dr. Antoniadis. All patients showed no significant paravalvular leakage or other complications, demonstrating excellent clinical performance of the product.

Case 1

01 Preoperative Assessment

The patient was a 73-year-old male. CT analysis revealed a stenotic tricuspid aortic valve with severely calcified and thickened leaflets. Measurements showed an annular perimeter of 73.9mm (mean diameter: 23.5mm), LVOT perimeter of 70.9mm (mean diameter: 22.2mm), sinus widths of 29.5mm/33.2mm/32.3mm, mean STJ diameter of 27.5mm, ascending aorta mean diameter of 29.3mm, and annular angulation of 50°.

02 CT Analysis Summary and Case Strategy

This was a typical tricuspid valve case. Based on annular perimeter, the TAV 24 valve from VitaFlow Liberty^® series was selected. Due to severe leaflet calcification and thickening, a 22mm balloon was used for pre-dilation, with initial deployment planned at about 2mm below the leaflet. Given the heavy calcification, post-dilation with a 22mm balloon was performed after deployment. The right access route was chosen as the primary approach.

Case Outcome

Final results showed 0mmHg transvalvular gradient, no significant paravalvular leakage, 6mm subvalvular implantation depth, good bilateral coronary flow, and no other complications.

Case 2

01 Preoperative Assessment

The patient was a 76-year-old female. Without preoperative CT reports available, the team decided to implant a TAV 27 valve after reviewing imaging and discussion, with 22mm balloon pre-dilation.

02 CT Analysis Summary and Case Strategy

This typical tricuspid valve case received a TAV 27 valve from VitaFlow Liberty^®. The LVOT appeared cylindrical with mildly calcified and thickened leaflets. Apart from the annulus, other planes showed insufficient anchoring force, requiring 22mm balloon pre-dilation. Initial deployment was planned about 2mm below the leaflet.

Case Outcome

After stent implantation, 22mm balloon post-dilation was performed. Final results showed 1mmHg transvalvular gradient, no significant paravalvular leakage, 5mm subvalvular implantation depth, good bilateral coronary flow, and no other complications.

Case 3

01 Preoperative Assessment

The patient was a 70-year-old male with severe aortic stenosis by echocardiography. CT showed a tricuspid aortic valve with severe calcification extending into the outflow tract. Measurements included annular perimeter of 83.5mm (mean diameter: 26.6mm), LVOT perimeter of 84.9mm (mean diameter: 27mm), sinus widths of 34.6mm/35.8mm/36.3mm, mean STJ diameter of 30.9mm, ascending aorta mean diameter of 37.3mm, and annular angulation of 51°.

02 CT Analysis Summary and Case Strategy

This typical tricuspid valve case received a TAV 30 valve based on annular perimeter. Due to heavy calcification extending into the outflow tract, the team opted for 20mm balloon pre-dilation to reduce annular injury risk. The right access route was suitable and selected as primary approach.

Case Outcome

Final results showed 5mmHg pressure gradient, no significant paravalvular leakage, 3mm subvalvular implantation depth, and no other complications.

03 Postoperative Evaluation

The surgical team highly commended VitaFlow Liberty^®'s clinical performance. One operator noted:

"The innovative electric retrievable design significantly improves deployment stability, offering simpler operation than traditional manual systems while demonstrating excellent anti-migration capability for precise positioning."

"The delivery system's exceptionally soft tip provides outstanding deliverability - even in complex cases like Case 3 with severe aortic arch calcification, the valve passed smoothly without complications. Even with calcification extending into the outflow tract, the valve's strong radial force and unique double-layer skirt design effectively expand calcified tissue while significantly reducing paravalvular leakage."

04 Conclusion

As the world's first commercially available electric retrievable TAVI system, VitaFlow Liberty^® has accelerated its overseas commercialization since becoming the first China-made TAVI system to obtain EU CE MDR certification in 2024. With over 150 procedures completed in CE-marked countries, its implant in Hungary represents another successfully entered high-growth European medical device market. As European market expansion continues, this innovation is expected to further accelerate global adoption, bringing Chinese medical solutions to a broader international patient population.

Istanbul, Denizli, and Izmir, Turkey — July 22-24, 2025 — The VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty^®), independently developed by MicroPort CardioFlow Medtech Corporation (02160.HK), has successfully completed the first five commercial implantations in Turkey. These procedures mark the official entry of VitaFlow Liberty^®, the world’s first motorized retrievable TAVI product, into Turkey, a transcontinental nation bridging Europe and Asia with a large population.

The procedures were guided by Prof. Jian’an Wang, an academician from the Second Affiliated Hospital of Zhejiang University, and Prof. Xianbao Liu, and were performed by Prof. Dr. Teoman Kilic from Kocaeli Üniversite Hastanesi, Prof. Dr. İsmail Doğu Kılıç from Pamukkale Üniversitesi Denizli Hastanesi, and Prof. Dr. Hakan Güneş from Tepecik EAH İzmir Hastanesi. Postoperative evaluations showed no significant paravalvular leakage or other complications in all five patients across the three hospitals, confirming the complete success of the procedures.

Case 1

The patient was a 91-year-old female with a tricuspid aortic valve and severe stenosis. CT measurements revealed an annulus circumference of 64.8 mm (mean diameter: 20.2 mm), an LVOT (left ventricular outflow tract) circumference of 66.6 mm (mean diameter: 20.3 mm), sinus widths of 28.3 mm / 29.5 mm / 30.1 mm, an STJ (sinotubular junction) mean diameter of 27.0 mm, an ascending aorta mean diameter of 31.8 mm, and an annulus angle of 50°.

This was a case of severely calcified tricuspid valve, with calcification extending into the outflow tract, posing a potential risk of paravalvular leakage (PVL). Due to the patient’s risk of left coronary artery occlusion, the teaching experts and operators decided to use an 18 mm balloon for pre-dilation angiography to assess coronary risk and assist in valve sizing. If a TAV21 valve was selected, high implantation would be performed; if a TAV24 valve was chosen, standard implantation would be adopted.

After 18 mm balloon pre-dilation, the TAV24 valve was selected. Mild residual PVL was observed post-implantation, so a 20 mm balloon post-dilation was performed. The final result showed a 4 mmHg pressure gradient, no significant PVL, an implantation depth of 2 mm at the non-coronary sinus and 5 mm at the opposite leaflet, and no other complications.

Case 2

The patient was an 82-year-old female with a tricuspid aortic valve, severe stenosis, and moderate regurgitation. CT measurements revealed an annulus circumference of 60.8 mm (mean diameter: 19.5 mm), an LVOT circumference of 58.7 mm (mean diameter: 18.3 mm), sinus widths of 37.6 mm / 28.4 mm / 28.9 mm, an STJ mean diameter of 25.4 mm, an ascending aorta mean diameter of 32.9 mm, and an annulus angle of 49°.

This was a classic tricuspid valve case with thickened and severely calcified leaflets. The annulus size was between the TAV24 and TAV21 models of VitaFlow Liberty^®. Given the heavy calcification and thickened leaflets, the operator determined that the straight-frame stent and supra-annular valve design of the product would provide better effective orifice area. Thus, an 18 mm balloon pre-dilation was performed, followed by implantation of the TAV21 valve with high positioning.

The final result showed no pressure gradient, no significant PVL, an implantation depth of 1 mm at the non-coronary sinus and 4 mm at the opposite leaflet, and no other complications.

Case 3

The patient was an 82-year-old female with a tricuspid aortic valve and severe stenosis. CT measurements revealed an annulus circumference of 77.1 mm (mean diameter: 23.9 mm), an LVOT circumference of 80.0 mm (mean diameter: 23.1 mm), sinus widths of 31.9 mm / 31.6 mm / 29.3 mm, an STJ mean diameter of 30.5 mm, an ascending aorta mean diameter of 34.4 mm, and an annulus angle of 58°.

This was a classic tricuspid valve case with mild calcification distributed along the leaflet edges. Based on the annulus circumference, the TAV27 valve from the VitaFlow Liberty^® series was selected. The operator concluded that the straight-frame stent and electric release function of the product would enhance deployment stability, so no pre-dilation was performed, and the valve was released at the standard position.

The final result showed no pressure gradient, no significant PVL, an implantation depth of 1 mm at the non-coronary sinus and 4 mm at the opposite leaflet, and no other complications.

After the procedures, all three Turkish operators highly praised the clinical performance of VitaFlow Liberty^®, noting that its delivery system enabled stable and precise valve deployment, while the retrievable function significantly improved procedural success rates. The single-operator design also made the procedures more efficient. They expressed hope for deeper collaboration with Chinese experts to benefit more patients in the future.

As a strategic hub connecting Europe and Asia, Turkey has always been an important partner in the Belt and Road Initiative. This Sino-Turkish medical collaboration not only exemplifies high-level international medical technology exchange but also serves as a vivid practice of the "Health Silk Road", demonstrating the fruitful outcomes of deepened cooperation in healthcare among Belt and Road countries.

Moving forward, the company will seize the opportunities presented by the high-quality development of the Belt and Road Initiative, leverage Turkey’s regional advantages as a bridge between Europe and Asia, and continue to promote the global expansion of innovative medical solutions, enabling more patients to benefit from China’s advancements in medical technology.

Hong Kong, China — Recently, the AnchorMan^® Left Atrial Appendage Closure System (AnchorMan^® LAAC system), independently developed by Shanghai MicroPort CardioAdvent Co., Ltd, a wholly-owned subsidiary of MicroPort CardioFlow Medtech Corporation (CardioFlow, 02160.HK), achieved its first clinical application in Hong Kong at Canossa Hospital – Hong Kong Asia Heart Centre. The procedure successfully implemented a stroke prevention solution for an elderly patient at high risk of stroke. Post-operation, the closure remained stable with no complications, marking a significant breakthrough in the strategic deployment of this innovative product in the Chinese market.

1. The procedure was completed by a team led by two specialists from Hong Kong Asian Heart Centre: Professor Yixian Lin, Director of Cardiology Department, and Dr. Manho Wong. As a leading authority in cardiovascular care in Hong Kong, the centre provided critical support for the successful completion of the procedure, leveraging its top-tier expert team and advanced technical capabilities.

Case Details

01 Preoperative Assessment

The patient was an 86-year-old female with paroxysmal atrial fibrillation (AF). Due to kidney disease, she could not take oral anticoagulants. Her CHA2DS2-VASc score was 4, and her HAS-BLED score was 3, indicating high stroke and bleeding risks. Preoperative transesophageal echocardiography (TEE) confirmed no thrombus in the left atrium or left atrial appendage (LAA).

02 Case Strategy and Outcomes

The LAA had a bilobed, cauliflower-shaped morphology, with an ostium diameter of approximately 21.81 mm and a depth of 25.38 mm. A 29 mm AnchorMan^® LAAC system was selected for the procedure. During the operation, the delivery sheath was rotated counterclockwise to access the superior lobe, and the closure was deployed using a combination of the "unsheathing method" and "push-pull technique." The case results showed optimal positioning of the closure in the LAA with stable anchoring confirmed via tug test. The compression ratio ranged between 17.2% and 20.7%, with no residual flow or other complications observed.

03 Postoperative Evaluation

The surgical team highly praised the clinical performance of the AnchorMan^® LAAC system and expressed interest in further collaboration. Professor Yixian Lin remarked post-procedure:

"The closure expanded evenly outward, achieving complete sealing of the LAA ostium. Moreover, during the tug test, the device remained firmly in place without displacement, demonstrating excellent stability."

04 Summary

Since its launch in China in early 2024, the AnchorMan^® LAAC system has shown strong momentum, achieving a milestone of 500 implants within just one year. Its business footprint has rapidly expanded from mainland China to Macau, and now to Hong Kong, where this successful procedure marks a continued deepening of its strategic presence in the Chinese market. Previously, the device also completed its first post-EU-certification implant in Poland, highlighting significant progress in its globalization strategy. As the product continues to expand in domestic and international markets, this innovative treatment is expected to provide superior therapeutic options for more AF patients worldwide.